Replies to post #218032 on Biotech Values

[DewDiligence]

MYL in-licenses Copaxone knock-off with monthly dosing:

https://www.prnewswire.com/news-releases/mylan-to-acquire-the-global-marketing-rights-to-a-once-monthly-glatiramer-acetate-product-through-an-investment-and-partnership-with-israeli-company-mapi-pharma-300626931.html

Mylan N.V…and Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, today announced that the two companies will partner on the development and commercialization of GA Depot, a long-acting Glatiramer Acetate product. Mylan is acquiring global marketing rights to the product.

GA Depot is a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis, or RRMS.

Just in time for MYL’s Investor Day webcast tomorrow (#msg-139451176).